Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies today presented a poster abstract at the 43rd American Society of Clinical Oncology (ASCO) Annual meeting. The poster, entitled "Preliminary Results of a Phase 1 Clinical Trial of CYT-6901," announced the preliminary data of a National Cancer Institute conducted and CytImmune Sciences sponsored Phase 1 trial of CYT-6091 (Aurimune), CytImmune's lead drug compound. The Phase 1 clinical trial was designed to investigate whether: (1) Aurimune will perform identically in humans as it did in preclinical studies and companion animals and (2) the fever side effect observed in preclinical studies can be easily managed and separated from hypotension - the dose limiting side effect of the active pharmaceutical ingredient.

"This is a tremendous opportunity for CytImmune," said Dr. Lawrence Tamarkin. "Presenting preliminary Phase 1 trial results to the leading body of international oncology experts helps pave the way for nanomedicines as the next generation of targeted cancer therapies and their use in improving the biodelivery of potent, but highly toxic therapeutics. We believe CYT-6091 has the potential to become a new, versatile therapeutic which may be used to treat a broad spectrum of solid tumors."

CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities.

To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby av
'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Post Your Comments:
(Date:11/5/2009)... ,, SADDLE RIVER, N.J., Nov. 5 /PRNewswire-F... provider of sales and marketing support to U.S. p...and operational results for the third quarter ende... announcement, Nancy Lurker, Chief Executive Offic...ues of $21.0 million were lower than last year by ...
(Date:11/5/2009)...SAN DIEGO, Nov. 5 CareFu...l device company created on Sept. 1 through the sp...oducts businesses, today reported increases in rev...st quarter of its fiscal 2010 and raised its full-...th our strong results during the first quarter whi...
(Date:11/5/2009)...LEXINGTON, Ky., Nov. 5 V...rd: VHGI) announced today that it has entered into...d assets to Wound Management Technologies, Inc. (W...,000 in cash and debt, 4,000,000 shares of WNDM st... to VHGI. WNDM closed at $2.00 per share on 11/4/...
Breaking Medicine Technology:PDI Reports 2009 Third Quarter Financial Results 2PDI Reports 2009 Third Quarter Financial Results 3PDI Reports 2009 Third Quarter Financial Results 4PDI Reports 2009 Third Quarter Financial Results 5PDI Reports 2009 Third Quarter Financial Results 6PDI Reports 2009 Third Quarter Financial Results 7PDI Reports 2009 Third Quarter Financial Results 8PDI Reports 2009 Third Quarter Financial Results 9PDI Reports 2009 Third Quarter Financial Results 10PDI Reports 2009 Third Quarter Financial Results 11CareFusion Reports First Quarter Results, Raises Full-Year Outlook 2CareFusion Reports First Quarter Results, Raises Full-Year Outlook 3CareFusion Reports First Quarter Results, Raises Full-Year Outlook 4CareFusion Reports First Quarter Results, Raises Full-Year Outlook 5CareFusion Reports First Quarter Results, Raises Full-Year Outlook 6CareFusion Reports First Quarter Results, Raises Full-Year Outlook 7CareFusion Reports First Quarter Results, Raises Full-Year Outlook 8CareFusion Reports First Quarter Results, Raises Full-Year Outlook 9CareFusion Reports First Quarter Results, Raises Full-Year Outlook 10CareFusion Reports First Quarter Results, Raises Full-Year Outlook 11CareFusion Reports First Quarter Results, Raises Full-Year Outlook 12OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3Miami Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 54845 1Miami Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets 54845 2The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States 54841 1The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States 54841 2The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States 54841 3The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States 54841 4Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 1Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 2Are You Connected 3F AIM and GASICORP Expand Global Reach Through Landmark Strategic Alliance 54836 3
...land Journal of Medicine employs Quest Diagnostics... Feb. 20 Testing of blood specimens may detect ...e the chronic form of lymphocytic leukemia (CLL) d...rrent issue of the New England Journal of Medic...ng of cellular changes that characterize the earli...
... Adam B. Smith, D.O., FACOS, of Fort Worth LAP-BA...rth metroplex chosen by Allergan Medical for "A Re...n (BIB) System to Assist in the Weight Management ...the safety and effectiveness of BIB, an inflatable... with a behavior modification program compared to ...
Other Medicine Technology:Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4Fort Worth Surgeon Chosen as Investigator in Clinical Trial for Weight-Loss Device 2
(Date:11/5/2009)...IV researchers have received two NIH grants of $1 ...t controlled personal health records to improve he...patients. , Both studies are funded through the ...einvestment Act. , One study will look at using...personal health record to help HIV patients, adher...
(Date:11/5/2009)...neck, NJ/ - November 3, 2009 The Cornea and Laser...y to determine if an investigational corneal inlay...ading glasses. Dr. Peter Hersh, the study doctor,...onal AcuFocus Corneal Inlay (ACI) is intended to ...hich is the loss of near vision, and reduce depend...
(Date:11/5/2009)... The goal of the “Hopes and...to increase awareness about the disease, raise fun...gram through an online raffle and auction of the q...patients.” , Calaba...very caregiver who helps take care of someone livi...
(Date:11/5/2009)... Emdat, a world leader in online-...r as its new CEO, effective immediately. , ...at , a world leader in online-based medical transc...fective immediately., , , , ,Emdat’s foundi...usiness, selected Olver to serve as CEO of the 10-...
(Date:11/5/2009)...N DIEGO, Nov. 5 Volcano ...lopment, manufacture and sales of products for the...l artery disease, today reported revenues of $53.9..., The results for the quarter ended September 30,...venues of $44.1 million in the third quarter of 20...
Breaking Medicine News(10 mins):Health News:Federal stimulus funds support studies geared to improving HIV care and prevention 2Health News:Near vision research study 2Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 2Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 3Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 4Health News:Caregiver's National Quilt Contest Supports ALS Association's Global Research Program 5Health News:Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider 2Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 2Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 3Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 4Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 5Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 6Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 7Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 8Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 9Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 10Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 11Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 12Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 13Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 14
...rally blow your brains out as one man in Vancouver...people who are struck by lightning are not hit dir...scharge jumps from the object that was hit. ... iPod while jogging, he was struck by lightning. T...
...riant A group of research scientist from t...es has discovered a gene variant which augments th... (Hepatology No. 46, 11 July 2007, DOI 10.1002/hep...e goes up two to three times higher. The particula...
...withdrawn men increase their chances of dying fr...t their more gregarious peers . The scienti...Northwestern University of Chicago, who publishe...d extensive and detailed examinations of the perso...
...echanisms underlying embryo development has taken ...n biologists specialized in the study of the frui...cialized in the design of mathematical models that...the Institute for Research in Biomedicine (IRB Bar...
...a man's performance in the bedroom, but as researc...rt function . This finding means that the ...an potentially save the lives of people with speci...g the drug when a patient has a failing right vent...
...cily, with an allergic reaction to counterfeit Col...,000 tubes of the substance were confiscated at th...he fake Colgate toothpaste, has pustules on his fa...hpaste in Sicily, and they are being analysed, ANS...
Other Medicine News:Health News:Gallstone Gene Discovered by Research Team 2Health News:Male Wallflowers-Watch Your Heart 2Health News:Understanding the Mechanism Underlying Embryo Development 2Health News:Understanding the Mechanism Underlying Embryo Development 3Health News:Viagra Improves Heart Function, Finds Study 2Health News:Viagra Improves Heart Function, Finds Study 3
...nse Webster fixed curve catheters are available in...ing multi-electrode tip configurations and several...rafted to precise and demanding specifications, us...ulti-step process incorporating proven wire-braidi...
...nse Webster offers a wide range of fixed curve cat...eeds of children and other patients with small ana...specifications using only the finest materials. A ... wire braiding and extrusion technologies results ...
Inquiry Steerable Diagnostic Catheters
...d clinicians in performing Ankle/Brachial Index (A... complete packet of information. It includes a 10-... can be viewed on any computer with a CD drive. It... ABI test, provides information on the materials t...
Medicine Products: